Increased recruitment of eosinophils in the bone marrow, blood, and inflamed tissues is a hallmark of most asthma phenotypes, and in general, increased numbers are correlated with disease severity and associated with decreased control and increased exacerbations. In vitro studies have also shown reduced levels of apoptosis in eosinophils from asthmatic patient. 1 In addition, more eosinophils and fewer apoptotic eosinophils are observed in biopsy specimens from asthmatic patients, and the persistence of these cells can have important clinical consequences, as supported by the correlation between the number of nonapoptotic eosinophils and the severity of asthma. 2 Therefore we hypothesized that, in addition to the increased numbers of eosinophils, their reduced apoptosis contributes to the persistent eosinophilia and is also associated with inflammation in asthmatic patients.
Recently, noneosinophilic asthma, based on the low numbers of eosinophils in induced sputum, has been reported to be a separate phenotype from eosinophilic asthma, as characterized by noneosinophilic inflammatory cells, particularly neutrophils. It has been reported that approximately 50% of asthma is associated with eosinophilic inflammation, with the rest being associated with increased neutrophil numbers in sputum samples. 3 Although researchers working with animal models of asthma and asthmatic patients identified the crucial role of eosinophilia and the T H 2 immune pathway in airway inflammation, some patients show a neutrophil-predominant disease with an absence of T H 2 cytokines. The number of neutrophils increased in patients with acute or persistent asthma and show correlation with a poor response to inhaled corticosteroids [4] [5] [6] and even negatively correlated with lung function. 7 To our knowledge, the mechanisms underlying neutrophilic asthma are less clear. T H 17 cells and bacterial colonization in the airways of asthmatic patients have been implicated as causes of neutrophilia in patients with severe asthma. 8, 9 However, a human anti-IL-17RA mAb named brodalumab had no effect on asthma control scores, symptomfree days, and FEV 1 . 10 Increased neutrophil numbers might reflect a non-T H 2-dominated mechanism and, possibly, a steroid-resistant asthma phenotype. The higher levels of neutrophils in sputum were observed in patients with severe compared with mild asthma. 11 Severe asthma represents approximately 5% to 10% of all asthma but accounts for 40% of the total cost for asthma care and 30% to 50% of asthma morbidity. 12, 13 Disposal of inflammatory cells is a critical goal for inflammatory disease therapeutics, and promoting inflammatory cell death is a potential strategy to achieve this. Therefore the development of apoptosis-inducing drugs, such as members of the inhibitors of antiapoptotic Bcl-2 family, might have potential as antiinflammatory agents. Depletion of Bcl-2 family protein was shown to have a protective role against allergic diseases, such as anaphylaxis.
14 ABT-737 is a small-molecule BH3 domain peptide mimetic developed by Oltersdorf et al 15 as an antitumor agent in 2005. This inhibitor can induce apoptosis in tumor cells by selectively binding and inhibiting the anti-apoptotic proteins Bcl-2, Bcl-XL, and Bcl-W 15 but has much lower affinity for Mcl-1.
16
ABT-737 has been suggested as a potential antitumor agent. 17 More recently, ABT-199, which is also named venetoclax, was shown to be a more selective high-affinity Bcl-2-inhibiting BH3 mimetic 18 and justly approved by the US Food and Drug Administration for use in patients with chronic lymphocytic leukemia. 19 However, the potential of ABT-737 or ABT-199 in the treatment of inflammatory diseases has been investigated only rarely.
In this study we evaluated the essential role of Bcl-2 expression and apoptosis regulation in inflammatory cells in response to allergen-induced airway inflammation. We also investigated whether inhibition of Bcl-2 by ABT-737/ABT-199 might have potential in attenuating airway inflammation, particularly in patients with corticosteroid-insensitive neutrophilic asthma.
METHODS

Experimental animals
Male C57BL/6 mice (wild-type, aged 6-8 weeks) were purchased from the Animal Center of Zhejiang University and housed in a conventional animal facility. Vav-Bcl-2 transgenic mice (male, aged 6-8 weeks, background on C57BL/6 mice) were a generous gift from Professor Andreas Strasser (Walter and Eliza Hall Institute of Medical Research). All protocols in this study were approved by the Ethics Committee for Animal Studies at Zhejiang University School of Medicine, China.
Peripheral blood collection from patients with severe asthma
Patients with severe asthma according to Global Initiative for Asthma guidelines were recruited from the clinical population at the Respiratory Department of the Second Affiliated Hospital of the Zhejiang University School of Medicine who were poor responders to corticoid treatment. Blood leukocytes were obtained from asthmatic patients and treated with dexamethasone, ABT-737, or ABT-199 in different doses ex vivo. Cleaved caspase-3-positive granulocytes in blood cells were assessed by using fluorescence-activated cell sorting (FACS). The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine. All the patients provided written informed consent and understood that their tissues would be used for research.
Preparation of ABT-737 and ABT-199
ABT-737 and ABT-199 (Selleck, Houston, Tex) were formulated in 30% propylene glycol, 5% Tween-80, and 65% D5W (5% dextrose in water, pH 4.2). 20 21 or were immunized intraperitoneally at day 0 with 20 mg of grade V chicken egg OVA (Sigma-Aldrich) in endotoxin-free PBS emulsified in 75 mL of complete Freund adjuvant (CFA; Sigma-Aldrich) plus 25 mL of PBS (OVA/CFA model). 22 On days 24, 25, and 26 (OVA/alum) or day 14 (OVA/CFA), mice were challenged with an aerosol of 1% (OVA/alum) or 0.1% (OVA/CFA) OVA in saline for 40 minutes by means of ultrasonic nebulization (DeVilbiss, Somerset, Pa). Mice in the dexamethasone groups received dexamethasone (Sigma-Aldrich) at 1 mg/kg administered intraperitoneally in PBS 2 hours after each OVA aerosol challenge. After achievement of anesthesia, mice in the ABT-737 (or ABT-199) group were treated by means of intratracheal administration of 100 mg of ABT-737 (or ABT-199) in 50 mL of vehicle 2 hours after each OVA challenge. Naive mice were challenged with normal saline alone. Twenty-four hours after the last OVA challenge, all mice were killed for analysis. Bronchoalveolar lavage (BAL) fluid was collected, and the lungs were removed to 4% paraformaldehyde (left lung) or kept in tissue-culture medium on ice for homogenization (right lung) and subsequent processing.
Induction of allergic airway inflammation
OVA/alum and OVA/CFA models were established as eosinophilic or neutrophilic airway inflammatory model respectively, as previously reported. 21, 22 As described in Fig E1 in this article's Online Repository at www.jacionline.org, OVA/CFA models challenged 1 or 3 times similarly indicated neutrophil-dominated airway inflammation; moreover, all of them were resistant to dexamethasone treatment.
Measurement of airway hyperresponsiveness
Airway responsiveness was determined invasively based on lung resistance after challenge with aerosolized methacholine (Sigma-Aldrich), as described previously. 21 Briefly, mice were challenged with methacholine aerosol in increasing concentrations (0, 1.5625, 3.125, 6.25, 12.5, and 25 mg/mL in saline) 24 hours after the final OVA challenge by using the Buxco FinePoint (Buxco Electronics, Troy, NY). Data on lung resistance were continuously collected, and mean values were selected to express changes in airway function and regarded as one form of inflammation expression.
BAL fluid and differential cell counts
Twenty-four hours after the final OVA challenge, mice were killed, and BAL cells were collected by means of slow injection of ice-cold PBS into the trachea through a 22-inch intravenous catheter, which was repeated 3 times. Total numbers of cells in BAL fluid were counted with a Neubauer chamber. In addition, after cytospin, based on Wright-Giemsa staining, numbers of 
Histopathologic evaluation of lung tissue
Lungs were fixed in 10% formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin and observed under a microscope. All slides were examined in a random blind fashion by 2 independent investigators.
Immunohistochemical analysis of Bcl-2 and Mcl-1 in lung tissue
The left lung was fixed in formalin, paraffin embedded, and cut into 4-mm sections, and immunohistochemistry was performed, as described previously.
23 Sections were exposed to 3% H 2 O 2 in methanol for 10 minutes to quench endogenous peroxidase activity, and nonspecific bindings were blocked by incubation in PBS containing 5% BSA for 30 minutes. Lung tissue sections were incubated with anti-Bcl-2 or anti-Mcl-1 antibody (Santa Cruz Biotechnology, Dallas, Tex) at a titer of 1:500 overnight at 48C. After washing, sections were incubated with the secondary antibody-biotinylated anti-mouse IgG (Thermo Fisher Scientific) for 1 hour and exposed to a substrate chromogen mixture for 10 minutes. Finally, the sections were counterstained with hematoxylin and examined under an Olympus BX51 microscope equipped with an Olympus DP70 digital camera and ACDSee5.0 software (Olympus, Shibuya-ku, Tokyo, Japan). Bcl-2 or Mcl-1 expression was determined in 10 fields per lung section for each mouse at 10 3 100 magnification and quantified as mean intensity by using Image-Pro Plus software 6.0 (Media Cybernetics, Rockville, Md).
Immunofluorescence analysis of Bcl-2 in BAL cells
BAL cells were collected to prepare cytospin slides and then fixed and stained, as previously reported. 24 Specimens were washed 3 times with PBS and fixed in 4% paraformaldehyde for 30 minutes, permeabilized with PBS containing 0.2% Triton X-100 for 5 minutes, blocked with antibody diluents of 5% BSA in PBS for 30 minutes, and washed 3 times with PBS. Then the samples were exposed to the appropriate primary antibody (Santa Cruz Biotechnology) diluted in PBS containing 5% BSA in a humidified chamber overnight at 48C. Sections were washed briefly 3 times with PBS and stained with secondary antibody (Thermo Fisher Scientific) diluted in PBS containing 5% BSA for 30 minutes at room temperature. The slides were then mounted with ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific) and finally placed under coverslips and viewed with a fluorescence microscope (Olympus).
Flow cytometric analysis of BAL cells
BAL cell suspensions were obtained from mice or in vitro medium at a specific time point, and cell-surface marker expression was assessed with the fluorescent dye-conjugated mouse antibodies Gr-1 (phycoerythrin [PE]-Cy7), CD11b (PE; eBioscience, San Diego, Calif), and Siglec-F (PE; BD PharMingen, San Jose, Calif) for 30 minutes at 48C. Based on surface marker staining, suspensions were cultured with Annexin V (fluorescein isothiocyanate) and propidium iodide (MultiSciences, Hangzhou, China) to assess apoptosis level in BAL cells. Data were acquired with a FACScalibur flow cytometer (FC500 and Fortessa; BD Biosciences, Sparks, Md) and analyzed with FlowJo software (version 7.6; TreeStar, San Carlos, Calif).
Eosinophils and neutrophils were marked as Gr-1 interm /Siglec-F 1 and
Gr-1 1 /CD11b 1 populations, respectively.
Statistical analysis
Results are presented as means 6 SEMs. Data were analyzed with the Student t test (1-tailed) or 1-way ANOVA, followed by the Tukey post hoc test with GraphPad Prism 6 software (GraphPad Software, La Jolla, Calif). Differences were considered statistically significant at a P value of less than .05. Data are expressed as means 6 SEMs of individual groups from 3 independent experiments. Values represent means 6 SEMs of 6 to 10 mice per group.
RESULTS
Corticosteroids induce apoptosis of eosinophils, but not neutrophils, both in vitro and in vivo
Eosinophilic or neutrophilic asthma-like airway inflammation was established according to schemes in Fig 1, A and C, respectively. As expected, BAL fluid from the OVA/alum model contained mainly eosinophils and fewer neutrophils (Fig 1, B) , and in the OVA/CFA mouse models (Fig 1, D) , we found a substantial infiltration of neutrophils in the airways, which was poorly controlled by dexamethasone, as previously reported. 22 Based on flow cytometric analysis, eosinophils and neutrophils cultured from BAL fluid of OVA/alum and OVA/CFA mouse models indicated high viability (see Figs E2 and E3 in this article's Online Repository at www.jacionline.org).
We next assessed the survival of inflammatory cells in the setting of allergic airway inflammation in the OVA/alum model. BAL cells were obtained from allergic mice and treated with 10
25 mol/L dexamethasone in vitro for 12 hours. Dexamethasone induced marked apoptosis in eosinophils compared with that in control mice (Fig 1, E) . In vivo the BAL cells from OVA/alum mice showed less infiltration of total inflammatory cells and lower eosinophils counts (Fig 1, G and H) , as well as higher levels of apoptotic eosinophils after dexamethasone treatment (Fig 1, I) .
We also investigated the effect of dexamethasone on neutrophil survival, as well as the curative effect on neutrophilic airway inflammation in vivo. However, flow cytometric analysis showed that dexamethasone did not affect neutrophil viability either in vitro or in vivo (Fig 1, F and L) , and there was no evidence of inhibition of neutrophilic airway inflammation in vivo at concentrations that synergized to reduce eosinophil viability and strongly attenuate eosinophilic airway inflammation (Fig 1, J and K) .
Increased Bcl-2 expression in BAL inflammatory cells in the setting of eosinophilic or neutrophilic airway inflammation
The small molecular inhibitors ABT-737 and ABT-199 were developed as a mimetic of a BH3-only protein with high affinity for Bcl-2, and therefore we tested the expression of the target of Bcl-2 inhibitors in inflammatory cells. Staining with an antibody against Bcl-2 and immunohistochemical analysis revealed that both OVA/alum-and OVA/CFA-induced allergic inflammation significantly increased Bcl-2 expression in granulocytes of lung sections compared with that seen in control mice (Fig 2, A, B , E, and F). This was further confirmed by using immunofluorescence assays of Bcl-2 expression in BAL inflammatory cells. The percentage of Bcl-2-positive macrophages increased from 17% in control mice to 45% in OVA/alum mice (Fig 2, C and D) and from 15% in control to 41% in OVA/CFA mice (Fig 2, G and  H) . Although almost no granulocytes were found in BAL fluid from control mice, 26% Bcl-2 1 BAL granulocytes were found in OVA/alum mice (Fig 2, C and D) , and 30% were found in OVA/ CFA mice (Fig 2, G and H) . In addition, we assessed the expression of Mcl-1 protein, representing a distinct group of the antiapoptotic family, in airway inflammatory cells and found no difference between mice with allergic asthma and control mice (see Fig E4 in this article' s Online Repository at www.jacionline.org). In summary, we found an increased expression of the anti-apoptotic protein Bcl-2 induced by allergen provocation in the airway. (Fig 1, A) or neutrophilic (Fig 1, C) airway inflammation models shown in Fig 1, B and D, respectively. E and F, Numbers of apoptotic ex vivo eosinophils (Fig 1, E) and neutrophils (Fig 1, F) were determined by using FACS. G-L, Total BAL cells (Fig 1, G and J) , eosinophils (Fig 1, H) , and neutrophils (Fig 1, K) were counted, and apoptotic eosinophils (Fig 1, I ) and neutrophils (Fig 1, L) were analyzed. PI, Propidium iodide. *P < .05, **P < .01, and ***P < .001. n.s., Not significant.
Delayed resolution of airway inflammation in vav-Bcl-2 transgenic mice
Sensitization and challenge with OVA resulted in a marked increase in the numbers of eosinophils, neutrophils, and macrophages in both wild-type and vav-Bcl-2 transgenic mice compared with those in nonsensitized and nonchallenged mice, in which few inflammatory cells other than macrophages were observed. Interestingly, we found delayed resolution of (Fig 2, A and E) , and their mean intensities were determined (Fig 2, B  and F) . C, D, G, and H, Intracellular Bcl-2 expression in BAL cells was assessed by using immunofluorescence assays (Fig 2, C and G) , and percentages of Bcl-2 1 cells were determined (Fig 2, D and H) . ***P < .001.
inflammatory cell recruitment in the airways of vav-Bcl-2 transgenic mice compared with wild-type mice (Fig 3, A-C) . These results were also confirmed by means of analysis of the lung tissue pathology (Fig 3, D) , which further strengthened the conclusion that the overexpressed antiapoptotic protein Bcl-2 extended the survival time of inflammatory cells. Analysis of homogenate supernatants from lung tissues showed higher and longer IL-4 and IL-5 expression in OVA-sensitized and challenged vav-Bcl-2 transgenic mice (Fig 3, E and F) . Airway hyperresponsiveness (AHR) was similar between wild-type and vav-Bcl-2 transgenic mice 24 hours after the last OVA challenge (Fig 3, G) . As suggested by Egle et al, 25 vav-Bcl-2 transgenic mice indicated increased baseline levels of immune cells. However, the difference in various inflammation markers peaked at several days after allergen exposure (Fig 3) , which suggested that this was not only due to the baseline levels of the immune system but also to the clearance rate of inflammatory cells. We also observed reduced BAL eosinophil apoptosis in OVAsensitized/challenged vav-Bcl-2 transgenic mice compared with that in allergic wild-type mice (see Fig E5 in 
Bcl-2 inhibitors attenuate eosinophilic airway inflammation as efficiently as steroids
To begin with, we compared the Bcl-2 inhibitor ABT-737 with dexamethasone in terms of eosinophil viability. BAL cells were harvested from OVA/alum-sensitized and OVA-challenged mice and cultured with dexamethasone or ABT-737 treatment for 12 hours. Dexamethasone induced significant eosinophil apoptosis, as previously shown, and notably, ABT-737 promoted eosinophils apoptosis more than dexamethasone (Fig 4, A) . Thus ABT-737 is powerful in inducing inflammatory cell death.
Inflammatory cell recruitment into lung tissue and the alveolar space was analyzed to determine whether ABT-737 affects the regulation of allergen-induced eosinophilic asthma. As expected, the number of eosinophils increased in OVA-challenged mice compared with those in saline-treated control mice. Here we selected the suitable dose of ABT-737 or ABT-199 (100 mg/mouse) according to airway inflammatory cell recruitment and lung pathology (see Fig E6 in this article' s Online Repository at www.jacionline.org). Administration of ABT-737 (or ABT-199) to OVA-challenged mice significantly reduced total cell (Fig 4, B) and eosinophil (Fig 4, C) counts in the lung. In addition, we assessed the viability of BAL eosinophils (Gr-1 interm /Siglec-F 1 ) using flow cytometry and found that BAL eosinophil viability was markedly increased in OVAtreated mice compared with that in control mice (Fig 4, D) . In this established OVA allergy model, asthmatic mice were treated with ABT-737 at a dose with no BAL cell infiltration and no detectable damage to the airway epithelium. ABT-737-treated asthmatic mice had clearly enhanced eosinophils apoptosis. The proapoptotic effect of ABT-737 on inflammatory cells, mostly in granulocytes and macrophages, was verified by using immunochemical assays of activated caspase-9 and cleaved caspase-3 (Fig 4, E and F (Fig 4, G) . ABT-737 administered together with OVA sensitization and challenge significantly reduced AHR compared with that seen in allergic mice without treatment (Fig 4, H) . As expected, OVA-sensitized and challenged mice showed increased IL-4 and IL-5 production in the lung, and intratracheal administration of ABT-737 significantly reduced their expression (Fig 4, I and J) . As expected, in this case the response was similar to the proapoptotic effect on inflammatory cells and the suppression of inflammation in eosinophilic airway inflammation seen with dexamethasone (Fig 4, B-J) . In addition, ABT-737 reduced numbers of macrophages and lymphocytes on some levels, but no statistical difference was observed (see Fig E8 in this article's Online Repository at www.jacionline.org). We also found that ABT-199 reduced inflammatory cells infiltration, T H 2 cytokine levels, and AHR, as well as induced eosinophil apoptosis, and thus had a protective effect (see Fig E9 in this article's Online Repository at www.jacionline.org). Interestingly, these results indicate that ABT-737 and ABT-199 treatment after OVA allergy challenge effectively enhances eosinophil apoptosis, leading to reduced lung inflammation.
Bcl-2 inhibitors attenuate dexamethasone-resistant neutrophilic airway inflammation and airway responsiveness
Having determined the curative effect of ABT-737 and ABT-199 in eosinophilic airway inflammation, we then set out to assess the efficacy of the Bcl-2 antagonist in neutrophil-dominated airway inflammation. Corticosteroids are potent antiinflammatory drugs for the treatment of chronic inflammation; however, neutrophils are generally considered less responsive to corticosteroids than other inflammatory cells, such as eosinophils. Based on these findings, we compared the effects of ABT-737 and dexamethasone on neutrophil survival. BAL cells were collected and cultured for 12 hours with ABT-737 or dexamethasone, and neutrophil apoptosis was analyzed by means of FACS. We found marked apoptosis of neutrophils with ABT-737 but not with dexamethasone treatment (Fig 5, A) .
To further explore the inhibitory effect of ABT-737 or ABT-199 on neutrophilic airway inflammation, mice were treated with either ABT-737, ABT-199, or vehicle after OVA challenge. Analysis of BAL fluid showed that the allergen-induced accumulation of neutrophils accounted for the majority of inflammatory cells in the airways. Asthmatic mice treated with ABT-737 showed strong inhibition of total BAL cells and neutrophils infiltration, whereas dexamethasone induced no reduction in numbers of inflammatory cells (Fig 5, B and C) . More importantly, based on the gating of Gr-1
1
/CD11b
1 in FACS, neutrophils from asthmatic mice had higher viability than control cells (Fig 5, D) . Furthermore, ABT-737 had a powerful proapoptotic effect on neutrophils, but the level of neutrophil apoptosis did not change in dexamethasone-treated mice (Fig 5, D) , confirming that these cells are resistant to corticosteroids, as previously reported.
Immunohistochemical analysis revealed that a higher number of inflammatory cells, mostly granulocytes and macrophages, were positive for activated caspase-9 and cleaved caspase-3 in ABT-737-treated asthmatic mice (Fig 5, E and F (Fig 5, G) . The AHR of allergic mice treated with ABT-737 was significantly reduced compared with that of OVA/CFA-sensitized and challenged mice. However, dexamethasone had no effect on the AHR in neutrophilic airway inflammation (Fig 5, H) . The higher expression of IL-17 and the neutrophil chemokine KC in lung homogenates from asthmatic mice was reversed by administration of ABT-737 but not by dexamethasone (Fig 5, I and J) . In addition, the numbers of macrophages, but not lymphocytes, were decreased statistically by ABT-737 (see Fig E11 in OVA/alum models were established by using wild-type and vav-Bcl-2 transgenic mice. A-C, Total numbers of BAL cells (Fig 3, A) and differentiated eosinophils (Fig 3, B) and neutrophils (Fig 3, C) were determined. D, Histochemical staining (hematoxylin and eosin) was used to identify inflammatory cell recruitment. E and F, IL-4 and IL-5 levels in lung homogenates were measured by using ELISA. G, AHR assessed as the mean response to methacholine. *P < .05 and **P < .01. n.s., Not significant; Tg, transgenic. (Fig 4, B) , eosinophils (Fig 4, C) , and eosinophils (Fig 4, D) in apoptosis. E and F, Activated caspase-9 (Fig 4, E) and cleaved caspase-3 (Fig 4, F) in lung tissue described quantitatively. G, Evaluation of cell recruitment. H, AHR data: *P <.05, OVA/alum versus OVA/alum-ABT-737; #P < .05, OVA/alum versus OVA/alum-dexamethasone. I and J, IL-4 (Fig 4, I ) and IL-5 (Fig 4, J) levels in lung homogenates. *P < .05, **P < .01, and ***P < .001. n.s., Not significant.
FIG 5.
Bcl-2 inhibitor ABT-737 attenuates neutrophilic airway inflammation more efficiently than dexamethasone. A, Apoptotic neutrophils from ex vivo culture were determined. B-G, Effect of dexamethasone or ABT-737 on total cells (Fig 5, B) , neutrophils (Fig 5, C) , apoptotic neutrophils (Fig 5, D) , activated caspase-9 (Fig 5, E) , and cleaved caspase-3 (Fig 5, F) in the OVA/CFA model were assessed. G, Hematoxylin and eosin staining of lungs showing inflammatory cell recruitment. H, AHR data: *P < .05, OVA/CFA versus OVA/CFA-ABT-737. I and J, IL-17 (Fig 5, I ) and KC (Fig 5, J) concentrations in lung homogenates. *P < .05, **P < .01, and ***P < .001. n.s., Not significant. find a dramatic difference compared with the previous model (see Fig E1) , suggesting neutrophilic airway inflammation is not only an acute response.
Bcl-2 inhibitors induce apoptosis of T H 2, T H 17, and CD11c
1 dendritic cells in either an eosinophilic or neutrophilic airway inflammation mouse model Although asthma is classically associated with eosinophilia and T H 2 response, some patients show a neutrophil-predominant phenotype with a T H 17 immune response, especially those who are relatively insensitive to inhaled steroid treatment. 26 In this study Bcl-2 inhibitors promoted lung T H 2 and T H 17 apoptosis, whereas steroids only affected T H 2 (Fig 6) . As reported by Banuelos et al, 27 T H 17 cells had higher levels of Bcl-2, which may partially contribute to the sensitive response of ABT-737 or ABT-199 treatment on these cells. Pulmonary dendritic cells act as antigen-presenting cells and express numerous pattern recognition receptors on their cell surface; in addition, dendritic cells also gather in the airways in response to allergens and regulate the T H 2 response in patients with allergic asthma. 28, 29 We demonstrated that Bcl-2 inhibitors induce apoptosis of lung total dendritic cells (see Fig E13 in this article' s Online Repository at www. jacionline.org).
Inhibition of Bcl-2 efficiently induces apoptosis of granulocytes from patients with severe asthma
We have shown strong evidence both in vitro and in vivo of the potential of Bcl-2 inhibitors in treatment of airway inflammation, especially for the steroid-insensitive model. To explore whether Bcl-2 overexpression is essential for granulocyte survival, we treated blood granulocytes ex vivo from patients with severe asthma, which was diagnosed according to Global Initiative for Asthma guidelines. ABT-737 or ABT-199 treatment strongly induced the intracellular expression of cleaved caspase-3, indicating apoptosis. We found that blood granulocytes treated with ABT-737 or ABT-199 for 12 hours showed significantly higher expression of cleaved caspase-3, whereas the population of cleaved caspase-3-positive granulocytes did not increase appreciably in dexamethasone-treated cells (Fig 7, A and B) , and we also found a suggestion of obvious morphologic changes in ABT-737-or ABT-199-treated granulocytes (Fig 7, C) . The overwhelming majority of granulocytes are neutrophils, and therefore it appears likely that Bcl-2 inhibitors, but not dexamethasone, can induce apoptosis in the neutrophildominated granulocytes of patients with severe asthma. The 50% effective concentrations for ABT-737 and ABT-199 are 86.98 and 51.65 mmol/L, respectively (see Fig E14 in this article' s Online Repository at www.jacionline.org). 
DISCUSSION
In this study we demonstrated that inflammatory cells were recruited to the airways, as seen in BAL fluid. These cells showed increased viability in vivo and in vitro in mouse asthma models.
Higher expression of the antiapoptotic protein Bcl-2 in inflamed lungs was observed. More interestingly, overexpression of Bcl-2 in hematopoietic cells delayed resolution of inflammatory cells after allergen challenge. Furthermore, we found evidence A and B, Apoptotic granulocytes from patients with severe asthma analyzed by means of flow cytometry after ex vivo culture for 12 hours (Fig 7, A) and statistical results (Fig 7, B) . C, Cell morphologic changes were observed according to Wright-Giemsa staining. D, Schematic representation of the therapeutic effects of Bcl-2 antagonists in the setting of allergic airway inflammation. ***P < .001. n.s., Not significant. that inhibition of Bcl-2 by the selective inhibitors ABT-737 and ABT-199 significantly reduced airway inflammation and AHR, especially in the setting of corticosteroid-insensitive neutrophilic airway inflammation (Fig 7, D) .
Effective immune regulation depends on the balance between cell proliferation and cell death. Programmed cell death (apoptosis) is essential for normal development and tissue homeostasis in multicellular organisms. 30 The intrinsic apoptosis pathway, which requires Bcl-2 family proteins, is activated by various cytotoxic insults, such as microbial infection, DNA damage, and growth factor deficiency, and is strictly controlled by interactions of the proapoptotic proteins. 31 The release of proapoptotic factors into the cytosol promotes activation of caspase-9 and, subsequently, caspase-3, leading to cell death. As reported, the BH3 mimetic ABT-737 can induce DNA damage and genomic instability in vitro, which is responsible for cell death. 32 The key antiapoptotic protein Bcl-2 is essential for survival of granulocytes, such as eosinophils and neutrophils. 33 Higher expression of Bcl-2 protein in inflammatory cells from mice with allergic lung tissue was observed in mouse models of both eosinophilic and neutrophilic airway inflammation. The increased inflammatory cell infiltration and persistent inflammation in vav-Bcl-2 transgenic mice showed that the higher expression of Bcl-2 sustained resistance to inflammatory cell death and inhibited the resolution of inflammation. As in previous research, mouse neutrophils overexpressing transgenic Bcl-2 showed strongly reduced spontaneous apoptosis. 34 ABT-737 and ABT-199 predominantly bind to Bcl-2, although with low affinity form myeloid cell leukemia sequences, such as Mcl-1. Interestingly, we found no significant change during airway inflammation in Mcl-1 protein expression. Furthermore, these Bcl-2 inhibitors proved effective in reducing either eosinophilic or neutrophilic airway inflammation in mouse models, with the latter model being particularly resistant to current clinically available corticosteroid treatment. Therefore induction of apoptosis in inflammatory cells based on binding Bcl-2 with its inhibitor might be an attractive strategy for the treatment of asthma and perhaps also other inflammatory airway diseases.
Corticosteroids have powerful anti-inflammatory effects, with their ability to inhibit inflammatory cell recruitment and downregulate inflammatory cytokine production in treatment against most inflammatory diseases. Taking asthma as an example, asthmatic patients treated with corticosteroid show a striking reduction in the numbers of activated eosinophils, mast cells, and T cells. Most symptoms might be well controlled with regular inhaled corticosteroids with or without long-acting b 2 -agonists. Use of low-dose inhaled corticosteroids has now become the first-line treatment for asthmatic patients. 35 However, a proportion of asthmatic patients do not respond to corticosteroids, even at higher doses or with supplementary therapy, and are regarded as corticosteroid resistant. 36 This was first described in asthmatic patients in 1968 37 and is now defined as asthma that shows no clinical improvement after treatment with high-dose (40 mg) oral prednisolone daily for 2 weeks. 38 In contrast to eosinophils, neutrophils are generally considered to be less responsive to corticosteroids, 39 and corticosteroids might even enhance their survival. 40 It has been reported that neutrophilic asthma is corticoid resistant or at least less sensitive. 41 This study provides an attractive strategy to clear inflammatory cells, especially neutrophils, in the setting of inflammatory airway disease. Our results showed that local treatment with ABT-737 or ABT-199 not only reduced eosinophil numbers in BAL fluid in a mouse model of eosinophilic asthma but also increased eosinophil apoptosis. More importantly, ABT-737 and ABT-199 also strongly reduced the number of neutrophils in a mouse model of neutrophilic asthma, with no detectable damage to the airway epithelium according to hematoxylin and eosin and terminal deoxynucleotidyl transferase dUTP nick end-labeling staining and E-cadherin, which represents epithelial barrier function (see Fig E15 in this article' s Online Repository at www.jacionline.org), 42 and no change in BAL cell infiltration after Bcl-2 inhibitor vehicle treatment in the setting of both eosinophilic and neutrophilic asthma (see Fig E16 in this article' s Online Repository at www.jacionline. org). Increased IL-17 levels in mice with neutrophilic asthma was also reduced by ABT-737 or ABT-199 administration, which suggested that IL-17 was involved in severe or corticosteroidinsensitive neutrophilic asthma. 8 One way to explain this phenomenon might be through the binding of ABT-737 or ABT-199 with overexpressed Bcl-2 proteins in inflammatory cells. These findings were further supported by ex vivo results. Inflammatory BAL cells cultured with dexamethasone and ABT-737 showed eosinophil apoptosis, and ABT-737 was more effective than dexamethasone in this process. In addition, the results showed that dexamethasone had hardly any effect on the survival of neutrophils, which is consistent with previous findings, and these cells were markedly more susceptible to ABT-737, providing an explanation for the reduced recruitment of neutrophils in vivo.
In addition to pulmonary inflammation, asthma is also characterized by AHR. AHR is defined as an exaggerated obstructive response of the airways to various pharmacologic, chemical, and physical stimuli. 43 For examples, researchers have focused on understanding the effects of cytokines, such as TNF-a, IL-13, IL-17A, and other cytokines, on mediating immune regulations in asthmatic patients. 44 As in the setting of asthma, AHR seems to be correlated with airway inflammation and remodeling. However, the detailed mechanisms underlying AHR development are still not fully understood. As mentioned above, the symptoms of a small portion of patients with severe asthma are poorly controlled by corticosteroids. This might be attributable to the limited effectiveness of the anti-inflammatory effects and tissue remodeling for corticosteroids, and the latter is associated with persistent AHR and irreversible lung function decrease. 45 We reported here that ABT-737 and ABT-199 could reduce AHR in the setting of corticosteroid-resistant neutrophilic asthma; indeed, the deeper mechanisms need further exploration. Interestingly, no obvious difference of AHR was found between allergensensitized/challenged wild-type and Bcl-2 transgenic mice.
In summary, we conclude that ABT-737 and ABT-199 are promising therapeutic agents against airway inflammation, especially against corticosteroid-insensitive neutrophilic airway inflammation.
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Key messages
d Increased levels of Bcl-2 protein were found to be responsible for the persistence of eosinophils and neutrophils in the setting of allergic airway inflammation.
d Delayed resolution of airway inflammation is found in vav-Bcl-2 transgenic mice.
d The Bcl-2 inhibitors ABT-737 or ABT-199 inhibit allergic airway inflammation, especially neutrophil-dominated and corticosteroid-insensitive asthma, by promoting the death of inflammatory cells.
